AbbVie and Coherus announce AmAb settlement

Jan 25, 2019

Coherus announces an 8th global deal with AbbVie for the commercialisation of biosimilar AmAb, under which Coherus has global, non-exclusive license rights which are royalty bearing.  Coherus’ US rights commence on 15 Dec 2023, just under a month after Momenta’s & Pfizer’s.

Print Page Mail Article